Amlitelimab Biosimilar – Anti-TNFSF4 mAb – Research Grade

Description of Amlitelimab Biosimilar - Anti-TNFSF4 mAb - Research Grade

Introduction

Amlitelimab Biosimilar, also known as Anti-TNFSF4 mAb, is a research grade antibody that targets the TNFSF4 protein. This protein, also known as OX40L, is a cytokine that plays a crucial role in the immune response and has been implicated in various autoimmune and inflammatory diseases. Amlitelimab Biosimilar is a promising therapeutic option for these conditions due to its ability to block the activity of TNFSF4. In this article, we will explore the structure, activity, and potential applications of Amlitelimab Biosimilar.

Structure of Amlitelimab Biosimilar

Amlitelimab Biosimilar is a monoclonal antibody, meaning it is derived from a single clone of immune cells. It is produced using recombinant DNA technology, where the gene for the antibody is inserted into a host cell, such as a Chinese hamster ovary (CHO) cell. The resulting cells then produce large quantities of Amlitelimab Biosimilar, which can be purified and used for research purposes.

The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. These chains are linked together by disulfide bonds and form a Y-shaped structure. The variable regions of the antibody, located at the tips of the Y, are responsible for binding to the TNFSF4 protein.

Activity of Amlitelimab Biosimilar

Amlitelimab Biosimilar works by binding to the TNFSF4 protein and preventing it from interacting with its receptor, OX40, on the surface of immune cells. This interaction is crucial for the activation and proliferation of T cells, which play a central role in the immune response. By blocking this interaction, Amlitelimab Biosimilar can inhibit the activity of T cells and reduce inflammation.

In addition to its role in the immune response, TNFSF4 has also been implicated in the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. By targeting this protein, Amlitelimab Biosimilar has the potential to effectively treat these conditions and improve patient outcomes.

Potential Applications of Amlitelimab Biosimilar

Amlitelimab Biosimilar is currently being studied for its potential use in various autoimmune and inflammatory diseases. In preclinical studies, it has shown promising results in the treatment of rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

In a phase I clinical trial, Amlitelimab Biosimilar was well-tolerated and showed a favorable safety profile. It also demonstrated a dose-dependent reduction in TNFSF4 levels in patients with rheumatoid arthritis. These results support the potential of Amlitelimab Biosimilar as a therapeutic option for these diseases.

In addition to its potential as a treatment, Amlitelimab Biosimilar can also be used as a research tool to further understand the role of TNFSF4 in various diseases. Its ability to specifically target this protein makes it a valuable tool for studying the immune response and developing new treatments for autoimmune and inflammatory conditions.

Conclusion

In conclusion, Amlitelimab Biosimilar is a research grade antibody that targets the TNFSF4 protein. Its structure, activity, and potential applications make it a promising therapeutic option for various autoimmune and inflammatory diseases. Further research and clinical trials are needed to fully understand the potential of this antibody and its role in treating these conditions. However, Amlitelimab Biosimilar shows great potential in improving patient outcomes and advancing our understanding of the immune response.

SDS-PAGE for Amlitelimab Biosimilar - Anti-TNFSF4 mAb

Amlitelimab Biosimilar - Anti-TNFSF4 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.